STOCK TITAN
  1. Home
  2. Sec-filings
  3. KRYS
  4. [Form 4] Krystal Biotech, Inc. Insider Trading Activity

Krystal Biotech (KRYS) director logs 25K-share sale and 3,691-share gift

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Krystal Biotech, Inc. director Dino A. Rossi reported dispositions of Common Stock on August 14, 2026. He made a bona fide gift of 3,691 shares to a charitable donor-advised fund and sold 25,000 shares in multiple open-market transactions at weighted average prices ranging from $325.5985 to $333.23 per share, as detailed in trade-level footnotes.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider ROSSI DINO A
Role Director
Sold 25,000 shs ($8.23M)
Type Security Shares Price Value
Gift Common Stock F1 3,691 $0.00 $0.00
Sale Common Stock F2 341 $325.5985 $111K
Sale Common Stock F3 2,287 $326.6028 $747K
Sale Common Stock F4 5,226 $327.3939 $1.71M
Sale Common Stock F5 1,687 $328.5152 $554K
Sale Common Stock F6 7,428 $329.6015 $2.45M
Sale Common Stock F7 4,896 $330.3558 $1.62M
Sale Common Stock F8 3,095 $331.4333 $1.03M
Sale Common Stock 40 $333.23 $13K
Holdings After Transaction: Common Stock — 50,000 shares (Direct)
Footnotes (8)
  1. F1. Represents a bona fide gift of Krystal Biotech, Inc.'s Common Stock to a charitable donor-advised fund.
  2. F2. The transaction was executed in multiple trades ranging from $325 to $325.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  3. F3. The transaction was executed in multiple trades ranging from $326.04 to $326.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  4. F4. The transaction was executed in multiple trades ranging from $327 to $327.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  5. F5. The transaction was executed in multiple trades ranging from $328.01 to $328.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  6. F6. The transaction was executed in multiple trades ranging from $329.01 to $329.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  7. F7. The transaction was executed in multiple trades ranging from $330 to $330.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  8. F8. The transaction was executed in multiple trades ranging from $331.02 to $331.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Shares sold 25,000 shares Total Common Stock sales reported on August 14, 2026
Gifted shares 3,691 shares Bona fide gift to a charitable donor-advised fund
Sale price (block 1) $325.5985 per share Weighted average price for 341 shares sold (price range $325–$325.96)
Sale price (block 2) $326.6028 per share Weighted average price for 2,287 shares sold (price range $326.04–$326.98)
Highest weighted price $331.4333 per share Weighted average price for 3,095 shares sold (range $331.02–$331.99)
Single-price trade $333.23 per share Price for 40 shares sold without a price-range footnote
bona fide gift financial
"Represents a bona fide gift of Krystal Biotech, Inc.'s Common Stock"
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
donor-advised fund financial
"gift of ... Common Stock to a charitable donor-advised fund"
A donor-advised fund is a charitable giving account that lets an individual or family deposit cash, stock, or other assets now, get an immediate tax benefit, and then recommend grants to charities over time. Think of it like a private charitable bucket you control without running a charity yourself; investors care because it’s a tax-efficient way to give appreciated securities, can change when and how donated shares enter the market, and affects personal and corporate tax planning.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
open market or private transaction financial
"Sale in open market or private transaction"

FAQ

What insider transactions did KRYS director Dino A. Rossi report?
Dino A. Rossi reported disposing of 28,691 shares of Krystal Biotech Common Stock on August 14, 2026, including 25,000 shares sold in the market and 3,691 shares gifted to a charitable donor-advised fund.

How many Krystal Biotech (KRYS) shares did Dino A. Rossi sell and at what prices?
He reported selling 25,000 shares of Krystal Biotech Common Stock in multiple trades with weighted average prices per share ranging from $325.5985 to $333.23, each price range detailed in separate footnotes.

Did Dino A. Rossi make any gifts of Krystal Biotech (KRYS) stock?
Yes. He reported a bona fide gift of 3,691 shares of Krystal Biotech Common Stock to a charitable donor-advised fund, recorded as a disposition coded as a gift on August 14, 2026.

Were the KRYS insider sales by Dino A. Rossi under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not checked, and the footnotes do not mention a trading plan, so the reported 25,000-share sales are not identified as made under a Rule 10b5-1 plan.

What do the weighted average prices mean in the KRYS Form 4?
Each sale line reflects a weighted average sale price for trades executed in a price range, such as $325–$325.96, with a footnote stating the insider will provide trade-by-trade details upon request.

What role does Dino A. Rossi hold at Krystal Biotech (KRYS)?
Dino A. Rossi is identified as a director of Krystal Biotech, Inc. in the Form 4. The reported transactions involve Common Stock held with direct ownership, as indicated by the filing’s ownership codes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ROSSI DINO A
(Last)(First)(Middle)
C/O KRYSTAL BIOTECH, INC.
2100 WHARTON STREET, SUITE 701
(Street)
PITTSBURGH PENNSYLVANIA 15203
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/14/2026G(1)3,691D$075,000D
Common Stock08/14/2026S341D$325.5985(2)74,659D
Common Stock08/14/2026S2,287D$326.6028(3)72,372D
Common Stock08/14/2026S5,226D$327.3939(4)67,146D
Common Stock08/14/2026S1,687D$328.5152(5)65,459D
Common Stock08/14/2026S7,428D$329.6015(6)58,031D
Common Stock08/14/2026S4,896D$330.3558(7)53,135D
Common Stock08/14/2026S3,095D$331.4333(8)50,040D
Common Stock08/14/2026S40D$333.2350,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents a bona fide gift of Krystal Biotech, Inc.'s Common Stock to a charitable donor-advised fund.
2. The transaction was executed in multiple trades ranging from $325 to $325.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
3. The transaction was executed in multiple trades ranging from $326.04 to $326.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
4. The transaction was executed in multiple trades ranging from $327 to $327.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
5. The transaction was executed in multiple trades ranging from $328.01 to $328.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
6. The transaction was executed in multiple trades ranging from $329.01 to $329.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
7. The transaction was executed in multiple trades ranging from $330 to $330.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
8. The transaction was executed in multiple trades ranging from $331.02 to $331.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Remarks:
/s/ Krish Krishnan, as attorney-in-fact for Dino A. Rossi08/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR